| Year |
Citation |
Score |
| 2020 |
McGrail DJ, Garnett J, Yin J, Dai H, Shih DJH, Lam TNA, Li Y, Sun C, Li Y, Schmandt R, Wu JY, Hu L, Liang Y, Peng G, Jonasch E, ... Menter D, et al. Proteome Instability Is a Therapeutic Vulnerability in Mismatch Repair-Deficient Cancer. Cancer Cell. PMID 32109374 DOI: 10.1016/J.Ccell.2020.01.011 |
0.367 |
|
| 2020 |
Sahni N, McGrail DJ, Garnett J, Yin J, Dai H, Shih DJH, Peng G, Menter D, Yates MS, Kopetz S, Lu K, Broaddus R, Mills GB, Lin SY. Abstract NG14: Proteome instability is an immunogenic therapeutic vulnerability in mismatch repair deficient cancer Cancer Research. 80. DOI: 10.1158/1538-7445.Am2020-Ng14 |
0.435 |
|
| 2019 |
Korphaisarn K, Morris V, Davis JS, Overman MJ, Fogelman DR, Kee BK, Dasari A, Raghav KPS, Shureiqi I, Trupti M, Wolff RA, Eng C, Menter DG, Hamilton S, Kopetz S. Signet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinoma. British Journal of Cancer. PMID 31406299 DOI: 10.1200/Jco.2017.35.4_Suppl.606 |
0.343 |
|
| 2019 |
Ravoori MK, Margalit O, Singh S, Kim SH, Wei W, Menter DG, DuBois RN, Kundra V. Magnetic Resonance Imaging and Bioluminescence Imaging for Evaluating Tumor Burden in Orthotopic Colon Cancer. Scientific Reports. 9: 6100. PMID 30988343 DOI: 10.1038/S41598-019-42230-W |
0.324 |
|
| 2019 |
Willauer AN, Liu Y, Pereira AAL, Lam M, Morris JS, Raghav KPS, Morris VK, Menter D, Broaddus R, Meric-Bernstam F, Hayes-Jordan A, Huh W, Overman MJ, Kopetz S, Loree JM. Clinical and molecular characterization of early-onset colorectal cancer. Cancer. PMID 30854646 DOI: 10.1002/Cncr.31994 |
0.318 |
|
| 2019 |
Menter DG, Davis JS, Broom BM, Overman MJ, Morris J, Kopetz S. Back to the Colorectal Cancer Consensus Molecular Subtype Future. Current Gastroenterology Reports. 21: 5. PMID 30701321 DOI: 10.1007/S11894-019-0674-9 |
0.331 |
|
| 2019 |
Varkaris A, Katsiampoura A, Davis JS, Shah N, Lam M, Frias RL, Ivan C, Shimizu M, Morris J, Menter D, Overman M, Tran H, Heymach J, Chun YS, Vauthey JN, et al. Circulating inflammation signature predicts overall survival and relapse-free survival in metastatic colorectal cancer. British Journal of Cancer. PMID 30636774 DOI: 10.1038/S41416-018-0360-Y |
0.337 |
|
| 2019 |
Frias RL, Lam M, Overman MJ, Morris VK, Fogelman DR, Kee BK, Dasari A, Raghav KPS, Shureiqi I, Jiang Z, Jensen-Loewe PA, Wolff RA, Eng C, Menter D, Kopetz S, et al. Meat consumption and BRAF mutation status in colorectal cancer. Journal of Clinical Oncology. 37. DOI: 10.1200/Jco.2019.37.15_Suppl.E15135 |
0.346 |
|
| 2019 |
Chung SW, Overman MJ, Morris VK, Fogelman DR, Kee BK, Dasari A, Raghav KPS, Shureiqi I, Jiang Z, Jensen-Loewe PA, Wolff RA, Eng C, Menter D, Kopetz S, Davis JS. The association between female hormonal supplementation and molecular types in colorectal cancer. Journal of Clinical Oncology. 37. DOI: 10.1200/Jco.2019.37.15_Suppl.E15133 |
0.343 |
|
| 2019 |
Nusrat M, Roszik J, Katkhuda R, Menter D, Raghav KPS, Morris VK, Sharma P, Allison JP, Blando JM, Maru DM, Lizee G, Janku F, Overman MJ, Kopetz S. Association of PIK3CA mutations (mut) with immune engagement and clinical benefit from immunotherapy in microsatellite stable (MSS) colorectal cancer (CRC) patients (pts). Journal of Clinical Oncology. 37: 3604-3604. DOI: 10.1200/Jco.2019.37.15_Suppl.3604 |
0.34 |
|
| 2019 |
Napolitano S, Carbone F, Menter DG, Troiani T, Genovese G, Kopetz S. Immune competent somatic mosaic model of colorectal cancer Annals of Oncology. 30. DOI: 10.1093/Annonc/Mdz253.063 |
0.349 |
|
| 2018 |
Kim SH, Roszik J, Cho SN, Ogata D, Milton DR, Peng W, Menter D, Ekmekcioglu S, Grimm EA. The COX2 effector microsomal PGE2 synthase-1 is a regulator of immunosuppression in cutaneous melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30538110 DOI: 10.1158/1078-0432.Ccr-18-1163 |
0.313 |
|
| 2018 |
Kanikarla-Marie P, Kopetz S, Hawk ET, Millward SW, Sood AK, Gresele P, Overman M, Honn K, Menter DG. Bioactive lipid metabolism in platelet "first responder" and cancer biology. Cancer Metastasis Reviews. PMID 30112590 DOI: 10.1007/S10555-018-9755-8 |
0.336 |
|
| 2018 |
Kanikarla-Marie P, Lam M, Sorokin AV, Overman MJ, Kopetz S, Menter DG. Platelet Metabolism and Other Targeted Drugs; Potential Impact on Immunotherapy. Frontiers in Oncology. 8: 107. PMID 29732316 DOI: 10.3389/Fonc.2018.00107 |
0.346 |
|
| 2018 |
Haemmerle M, Stone RL, Menter DG, Afshar-Kharghan V, Sood AK. The Platelet Lifeline to Cancer: Challenges and Opportunities. Cancer Cell. PMID 29657130 DOI: 10.1016/J.Ccell.2018.03.002 |
0.366 |
|
| 2018 |
Sakellariou-Thompson D, Forget M, Roszik J, Jackson KR, Kim YU, Crosby S, Hurd MW, Wu J, Jiang Z, Hwu P, Lizee G, Menter D, Kopetz S, Overman MJ, Haymaker CL, et al. Preclinical development of tumor-infiltrating lymphocyte therapy for metastatic colorectal cancer. Journal of Clinical Oncology. 36: 95-95. DOI: 10.1200/Jco.2018.36.5_Suppl.95 |
0.358 |
|
| 2018 |
Willauer AN, Loree JM, Pereira AAL, Lam M, Raghav KPS, Morris VK, Menter D, Shaw KR, Broaddus R, Meric-Bernstam F, Wang Y, Overman MJ, Kopetz S. Clinical and molecular characterization of early-onset colorectal cancer patients with inflammatory bowel disease. Journal of Clinical Oncology. 36: 689-689. DOI: 10.1200/Jco.2018.36.4_Suppl.689 |
0.302 |
|
| 2018 |
Raghav KPS, Loree JM, Morris J, Manuel S, Crosby S, Meric-Bernstam F, Menter D, Raymond V, Lanman RB, Talasaz A, Kopetz S. Detection and description of ERBB2 amplification using circulating cell free tumor DNA (ctDNA) genomic analysis in metastatic colorectal cancer (mCRC). Journal of Clinical Oncology. 36: 661-661. DOI: 10.1200/Jco.2018.36.4_Suppl.661 |
0.312 |
|
| 2018 |
Nusrat M, Roszik J, Katkhuda R, Menter D, Raghav KPS, Morris VK, Sharma P, Allison JP, Blando JM, Maru DM, Overman MJ, Kopetz S. Association of phosphatidylinositol 3-kinase (PI3K) pathway activation with increased immune checkpoint expression in colorectal cancer (CRC) patients. Journal of Clinical Oncology. 36: 653-653. DOI: 10.1200/Jco.2018.36.4_Suppl.653 |
0.354 |
|
| 2018 |
Loree JM, Strickler JH, Pereira AAL, Lam M, Raghav KPS, Morris VK, Menter D, Banks K, Nagy RJ, Raymond V, Overman MJ, Talasaz A, Lanman RB, Kopetz S. Serial monitoring of ctDNA to highlight mutation profiles in colorectal cancer. Journal of Clinical Oncology. 36: 641-641. DOI: 10.1200/Jco.2018.36.4_Suppl.641 |
0.321 |
|
| 2018 |
Lam M, Pereira AAL, Kanikarla Marie P, Davis JS, Yu RX, Morris J, Manyam GC, Broom BM, Maru DM, Katkhuda R, Menter D, Kopetz S. Consensus molecular subtypes (CMS), markers of systemic inflammation (SI) and clinicopathological parameters in colorectal cancer (CRC). Journal of Clinical Oncology. 36: e15600-e15600. DOI: 10.1200/Jco.2018.36.15_Suppl.E15600 |
0.311 |
|
| 2018 |
Mehrvarz Sarshekeh A, Loree JM, Manyam GC, Pereira AAL, Raghav KPS, Lam M, Davis JS, Dasari A, Morris VK, Menter D, Eng C, Broaddus R, Routbort M, Luthra R, Maru DM, et al. The characteristics of ARID1A mutations in colorectal cancer. Journal of Clinical Oncology. 36: 3595-3595. DOI: 10.1200/Jco.2018.36.15_Suppl.3595 |
0.306 |
|
| 2018 |
Nusrat M, Oh J, Jiang Z, Dasari A, Fogelman DR, Kee BK, Menter D, Raghav KPS, Morris VK, Wu J, Meric-Bernstam F, Morris J, Overman MJ, Kopetz S. Proteomic profiling of phosphatidylinositol 3-kinase (PI3K) altered metastatic colorectal cancer (mCRC) after protein kinase B (Akt) inhibition: Insulin like growth factor 1 receptor (IGF1R) mediates adaptive resistance. Journal of Clinical Oncology. 36: 3549-3549. DOI: 10.1200/Jco.2018.36.15_Suppl.3549 |
0.394 |
|
| 2017 |
Loree JM, Pereira AA, Lam M, Willauer AN, Raghav K, Dasari A, Morris VK, Advani SM, Menter DG, Eng C, Shaw K, Broaddus R, Routbort MJ, Liu Y, Morris J, et al. Classifying colorectal cancer by tumor location rather than sidedness highlights a continuum in mutation profiles and Consensus Molecular Subtypes. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29180604 DOI: 10.1158/1078-0432.Ccr-17-2484 |
0.368 |
|
| 2017 |
Clarke CN, Lee MS, Wei W, Manyam G, Jiang ZQ, Lu Y, Morris J, Broom B, Menter D, Vilar-Sanchez E, Raghav K, Eng C, Chang GJ, Simon I, Bernards R, et al. Proteomic Features of Colorectal Cancer Identify Tumor Subtypes Independent of Oncogenic Mutations and Independently Predict Relapse-Free Survival. Annals of Surgical Oncology. PMID 28936799 DOI: 10.1245/S10434-017-6054-5 |
0.396 |
|
| 2017 |
Menter DG, Kopetz S, Hawk E, Sood AK, Loree JM, Gresele P, Honn KV. Platelet "first responders" in wound response, cancer, and metastasis. Cancer Metastasis Reviews. PMID 28730545 DOI: 10.1007/S10555-017-9682-0 |
0.332 |
|
| 2017 |
Lam M, Roszik J, Kanikarla-Marie P, Davis JS, Morris J, Kopetz S, Menter DG. The potential role of platelets in the consensus molecular subtypes of colorectal cancer. Cancer Metastasis Reviews. PMID 28681242 DOI: 10.1007/S10555-017-9678-9 |
0.365 |
|
| 2017 |
Kanikarla-Marie P, Lam M, Menter DG, Kopetz S. Platelets, circulating tumor cells, and the circulome. Cancer Metastasis Reviews. PMID 28667367 DOI: 10.1007/S10555-017-9681-1 |
0.356 |
|
| 2017 |
Lin SH, Raju GS, Huff C, Ye Y, Gu J, Chen JS, Hildebrandt MAT, Liang H, Menter DG, Morris J, Hawk E, Stroehlein JR, Futreal A, Kopetz S, Mishra L, et al. The somatic mutation landscape of premalignant colorectal adenoma. Gut. PMID 28607096 DOI: 10.1136/Gutjnl-2016-313573 |
0.323 |
|
| 2017 |
Rigoutsos I, Lee SK, Nam SY, Anfossi S, Pasculli B, Pichler M, Jing Y, Rodriguez-Aguayo C, Telonis AG, Rossi S, Ivan C, Catela Ivkovic T, Fabris L, Clark PM, Ling H, ... ... Menter D, et al. N-BLR, a primate-specific non-coding transcript leads to colorectal cancer invasion and migration. Genome Biology. 18: 98. PMID 28535802 DOI: 10.1186/S13059-017-1224-0 |
0.308 |
|
| 2017 |
Katsiampoura A, Raghav K, Jiang ZQ, Menter DG, Varkaris A, Morelli MP, Manuel S, Wu J, Sorokin AV, Rizi BS, Bristow C, Tian F, Airhart S, Cheng M, Broom BM, et al. Modeling of Patient Derived Xenografts in Colorectal Cancer. Molecular Cancer Therapeutics. PMID 28468778 DOI: 10.1158/1535-7163.Mct-16-0721 |
0.373 |
|
| 2017 |
Korphaisarn K, Karlyle Morris V, Overman MJ, Fogelman DR, Kee BK, Pratap Singh Raghav K, Manuel S, Shureiqi I, Wolff RA, Eng C, Menter D, Hamilton SR, Kopetz S, Dasari A. FBXW7 missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinoma. Oncotarget. PMID 28424412 DOI: 10.18632/Oncotarget.16848 |
0.347 |
|
| 2017 |
Parseghian C, Parikh NU, Wu JY, Jiang ZQ, Henderson LD, Tian F, Pastor B, Ychou M, Raghav K, Dasari A, Fogelman D, Katsiampoura A, Menter DG, Wolff RA, Eng C, et al. Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28280091 DOI: 10.1158/1078-0432.Ccr-16-3138 |
0.404 |
|
| 2017 |
Lee MS, Menter DG, Kopetz S. Right Versus Left Colon Cancer Biology: Integrating the Consensus Molecular Subtypes. Journal of the National Comprehensive Cancer Network : Jnccn. 15: 411-419. PMID 28275039 DOI: 10.6004/Jnccn.2017.0038 |
0.355 |
|
| 2017 |
Sorokin A, Bitner L, Wu J, Menter D, Kopetz S, Morris VK. Antitumor activity of panRAF inhibition in BRAF V600E metastatic colorectal cancer. Journal of Clinical Oncology. 35: 616-616. DOI: 10.1200/Jco.2017.35.4_Suppl.616 |
0.391 |
|
| 2017 |
Loree JM, Lam M, Morris J, Overman MJ, Raghav KPS, Eng C, Dasari A, Kee BK, Fogelman DR, Wolff RA, Jiang Z, Davis JS, Shaw KR, Broaddus R, Routbort M, ... ... Menter D, et al. RAS heterogeneity as a prognostic marker in metastatic colorectal cancer. Journal of Clinical Oncology. 35: 586-586. DOI: 10.1200/Jco.2017.35.4_Suppl.586 |
0.335 |
|
| 2017 |
Korphaisarn K, Chou C, Xia W, Clarke C, Davis JS, Liao H, Crosby S, Manuel S, Wu J, Menter D, Hung M, Kopetz S. Arginine methylation of EGFR in circulating tumor cells: A new biomarker for predicting resistance to anti-EGFR agents. Journal of Clinical Oncology. 35: 3590-3590. DOI: 10.1200/Jco.2017.35.15_Suppl.3590 |
0.34 |
|
| 2017 |
Reilley M, Basu S, Katkhuda R, Patterson N, Chen T, Blando JM, Menter D, Maru DM, Allison JP, Kopetz S, Sharma P, Overman MJ. Prognostic implications of TAMs in colorectal cancer hepatic metastases. Journal of Clinical Oncology. 35: 3574-3574. DOI: 10.1200/Jco.2017.35.15_Suppl.3574 |
0.343 |
|
| 2017 |
Loree JM, Korphaisarn KK, Lam M, Morris VK, Raghav KP, Overman MJ, Eng C, Dasari A, Kee BK, Fogelman D, Wolff RA, Shaw K, Broaddus R, Routbort MJ, Luthra R, ... ... Menter DG, et al. Abstract 4742:APCWT/RASWT/BRAFWTtumors represent an under recognized poor prognostic group of right sided colorectal cancer Cancer Research. 77: 4742-4742. DOI: 10.1158/1538-7445.Am2017-4742 |
0.34 |
|
| 2017 |
Inoue A, Rizi BS, Carugo A, Seth S, Bristow C, Genovese G, Viale A, Menter DG, Kopetz S, Draetta GF. Abstract 414: Identifying selective vulnerabilities in colorectal cancer molecular subtypes usingin vivofunctional genomic screens Cancer Research. 77: 414-414. DOI: 10.1158/1538-7445.Am2017-414 |
0.37 |
|
| 2017 |
Davis JS, Yu R, Banerjee M, Jiang Z, Menter DG, Guinney J, Morris J, Broom BM, Maru D, Manyam GC, Chang S, Kopetz S. Distinct Patient and Tumor Characteristics of the Consensus Molecular Subtypes of Colorectal Cancer Gastroenterology. 152: S880. DOI: 10.1016/S0016-5085(17)33008-1 |
0.371 |
|
| 2016 |
Batth IS, Mitra A, Manier S, Ghobrial IM, Menter D, Kopetz S, Li S. Circulating Tumor Markers: Harmonizing the yin and yang of CTCs and ctDNA for precision medicine. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 27998963 DOI: 10.1093/Annonc/Mdw619 |
0.305 |
|
| 2016 |
Raghav K, Morris V, Tang C, Morelli P, Amin HM, Chen K, Manyam GC, Broom B, Overman MJ, Shaw K, Meric-Bernstam F, Maru D, Menter D, Ellis LM, Eng C, et al. MET amplification in metastatic colorectal cancer: An acquired response to EGFR inhibition, not a de novo phenomenon. Oncotarget. PMID 27421137 DOI: 10.18632/Oncotarget.10559 |
0.362 |
|
| 2016 |
Kim SH, Hashimoto Y, Cho SN, Roszik J, Milton DR, Dal F, Kim SF, Menter DG, Yang P, Ekmekcioglu S, Grimm EA. Microsomal PGE2 synthase-1 regulates melanoma cell survival and associates with melanoma disease progression. Pigment Cell & Melanoma Research. PMID 26801201 DOI: 10.1111/Pcmr.12455 |
0.354 |
|
| 2016 |
Morris VK, Wu J, Adam L, Tian F, Gagea M, Hong DS, Menter D, Kopetz S. Role of MEK inhibition in improving anti-tumor responses in xenograft models of BRAF-mutated metastatic colorectal cancer. Journal of Clinical Oncology. 34: 265-265. DOI: 10.1200/Jco.2016.34.4_Suppl.265 |
0.348 |
|
| 2016 |
Dasari A, Overman MJ, Fogelman DR, Kee BK, Menter D, Raghav KPS, Morris VK, Oh J, Wu J, Jiang Z, Tian F, Adam L, Brimer M, Morris J, Meric-Bernstam F, et al. A phase II and co-clinical study of an AKT inhibitor in patients (pts) with biomarker-enriched, previously treated metastatic colorectal cancer (mCRC). Journal of Clinical Oncology. 34: 3563-3563. DOI: 10.1200/Jco.2016.34.15_Suppl.3563 |
0.37 |
|
| 2016 |
Reilley M, Blando JM, Katkhuda R, Menter D, Sharma P, Allison JP, Kopetz S, Maru DM, Overman MJ. Immunologic profiling of consensus molecular subtype (CMS) stratified colorectal cancer (CRC) primary and liver metastectomy specimens: Implications for immune targeting of proficient mismatch repair CRC. Journal of Clinical Oncology. 34: 3520-3520. DOI: 10.1200/Jco.2016.34.15_Suppl.3520 |
0.318 |
|
| 2016 |
Raghav KPS, Overman MJ, Yu R, Meric-Bernstam F, Menter D, Kee BK, Muranyi A, Singh S, Routbort M, Chen K, Shaw KR, Shanmugam K, Maru DM, Fakih M, Kopetz S. HER2 amplification as a negative predictive biomarker for anti-epidermal growth factor receptor antibody therapy in metastatic colorectal cancer. Journal of Clinical Oncology. 34: 3517-3517. DOI: 10.1200/Jco.2016.34.15_Suppl.3517 |
0.344 |
|
| 2016 |
Lee MS, Advani SM, Morris J, Jiang Z, Manyam GC, Menter D, Broom BM, Eng C, Overman MJ, Maru DM, Hamilton SR, Kopetz S. Association of primary (1°) site and molecular features with progression-free survival (PFS) and overall survival (OS) of metastatic colorectal cancer (mCRC) after anti-epidermal growth factor receptor (αEGFR) therapy. Journal of Clinical Oncology. 34: 3506-3506. DOI: 10.1200/Jco.2016.34.15_Suppl.3506 |
0.344 |
|
| 2016 |
Kim S, Hashimoto Y, Cho S, Roszik J, Milton DR, Dal F, Kim SF, Menter DG, Yang P, Ekmekcioglu S, Grimm EA. Abstract 2285: Microsomal PGE2 synthase-1 regulates melanoma cell survival and associates with melanoma disease progression Cancer Research. 76: 2285-2285. DOI: 10.1158/1538-7445.Am2016-2285 |
0.383 |
|
| 2016 |
Lin S, Raju GS, Huff C, Gu J, Chen J, Kopetz S, Menter DG, Hawk E, Mishra L, Ye Y, Wu X. Abstract 143: Mutational landscape of colorectal adenomas reveals potential signatures for progression Cancer Research. 76: 143-143. DOI: 10.1158/1538-7445.Am2016-143 |
0.343 |
|
| 2015 |
Fang L, Lu W, Choi HH, Yeung SC, Tung JY, Hsiao CD, Fuentes-Mattei E, Menter D, Chen C, Wang L, Wang J, Lee MH. ERK2-Dependent Phosphorylation of CSN6 Is Critical in Colorectal Cancer Development. Cancer Cell. 28: 183-97. PMID 26267535 DOI: 10.1016/J.Ccell.2015.07.004 |
0.393 |
|
| 2015 |
Chen ZY, Raghav K, Lieu CH, Jiang ZQ, Eng C, Vauthey JN, Chang GJ, Qiao W, Morris J, Hong D, Hoff P, Tran H, Menter DG, Heymach J, Overman M, et al. Cytokine profile and prognostic significance of high neutrophil-lymphocyte ratio in colorectal cancer. British Journal of Cancer. 112: 1088-97. PMID 25688736 DOI: 10.1038/Bjc.2015.61 |
0.356 |
|
| 2015 |
Morris VK, James B, Tian F, Jiang Z, Overman MJ, Maru DM, Menter D, Powis G, Kopetz S. Acquired mutations in MAPK signaling pathway following initial pharmacological response in BRAF-mutated metastatic colorectal cancer (mCRC). Journal of Clinical Oncology. 33: 629-629. DOI: 10.1200/Jco.2015.33.3_Suppl.629 |
0.328 |
|
| 2015 |
Clarke C, Lee MS, Manyam GC, Jiang Z, Tian F, Lu Y, Morris J, Broom BM, Menter D, Vilar Sanchez E, Raghav KPS, Eng C, Chang GJ, Overman MJ, Maru DM, et al. Proteomic features of colorectal cancer independently predict relapse-free survival. Journal of Clinical Oncology. 33: 616-616. DOI: 10.1200/Jco.2015.33.3_Suppl.616 |
0.382 |
|
| 2015 |
Lee MS, Clarke C, Jiang Z, Manyam GC, Tian F, Lu Y, Morris J, Broom BM, Menter D, Vilar Sanchez E, Shureiqi I, Raghav KPS, Eng C, Chang GJ, Simon I, et al. Proteomic signatures of colorectal cancer to identify distinct and reproducible subgroups independent of oncogenic mutations. Journal of Clinical Oncology. 33: 580-580. DOI: 10.1200/Jco.2015.33.3_Suppl.580 |
0.398 |
|
| 2015 |
Lee MS, Clarke C, Jiang Z, Manyam GC, Tian F, Lu Y, Morris J, Broom BM, Menter D, Vilar Sanchez E, Shureiqi I, Raghav KPS, Eng C, Chang GJ, Simon I, et al. Proteomic signatures of colorectal cancer to identify distinct and reproducible subgroups and to reflect prognosis. Journal of Clinical Oncology. 33: 3612-3612. DOI: 10.1200/Jco.2015.33.15_Suppl.3612 |
0.343 |
|
| 2015 |
Advani SM, Lee MS, Overman MJ, Fogelman D, Kee BK, Manuel SD, Davis J, Morris VK, Clarke CN, Daniel CR, Menter DG, Hamilton SR, Maru DM, Kopetz S. Abstract 4763: Correlation of CpG island methylation with clinical and pathologic characteristics in metastatic colorectal cancer patients Cancer Research. 75: 4763-4763. DOI: 10.1158/1538-7445.Am2015-4763 |
0.323 |
|
| 2014 |
Menter DG, Patterson SL, Logsdon CD, Kopetz S, Sood AK, Hawk ET. Convergence of nanotechnology and cancer prevention: are we there yet? Cancer Prevention Research (Philadelphia, Pa.). 7: 973-92. PMID 25060262 DOI: 10.1158/1940-6207.Capr-14-0079 |
0.355 |
|
| 2014 |
Menter DG, Tucker SC, Kopetz S, Sood AK, Crissman JD, Honn KV. Platelets and cancer: a casual or causal relationship: revisited. Cancer Metastasis Reviews. 33: 231-69. PMID 24696047 DOI: 10.1007/S10555-014-9498-0 |
0.35 |
|
| 2014 |
Yang P, Cartwright C, Efuet E, Hamilton SR, Wistuba II, Menter D, Addington C, Shureiqi I, Newman RA. Cellular location and expression of Na+, K+ -ATPase α subunits affect the anti-proliferative activity of oleandrin. Molecular Carcinogenesis. 53: 253-63. PMID 23073998 DOI: 10.1002/Mc.21968 |
0.374 |
|
| 2013 |
Charo C, Holla V, Arumugam T, Hwang R, Yang P, Dubois RN, Menter DG, Logsdon CD, Ramachandran V. PGE2 Regulates Pancreatic Stellate Cell Activity Via The EP4 Receptor Pancreatology. 13. DOI: 10.1016/J.Pan.2012.12.121 |
0.301 |
|
| 2012 |
Menter DG, Dubois RN. Prostaglandins in cancer cell adhesion, migration, and invasion. International Journal of Cell Biology. 2012: 723419. PMID 22505934 DOI: 10.1155/2012/723419 |
0.375 |
|
| 2012 |
Hawk ET, Menter DG, Patterson S, Swank MW, DuBois RN. Abstract 3251: Linking prostaglandin E2 signaling, lipid rafts, and DNA protein kinase Cancer Research. 72: 3251-3251. DOI: 10.1158/1538-7445.Am2012-3251 |
0.386 |
|
| 2011 |
Menter DG, Ramsauer VP, Harirforoosh S, Chakraborty K, Yang P, Hsi L, Newman RA, Krishnan K. Differential effects of pravastatin and simvastatin on the growth of tumor cells from different organ sites. Plos One. 6: e28813. PMID 22216116 DOI: 10.1371/Journal.Pone.0028813 |
0.404 |
|
| 2011 |
Holla VR, Wu H, Shi Q, Menter DG, DuBois RN. Nuclear orphan receptor NR4A2 modulates fatty acid oxidation pathways in colorectal cancer. The Journal of Biological Chemistry. 286: 30003-9. PMID 21757690 DOI: 10.1074/Jbc.M110.184697 |
0.378 |
|
| 2011 |
Campbell SE, Rudder B, Phillips RB, Whaley SG, Stimmel JB, Leesnitzer LM, Lightner J, Dessus-Babus S, Duffourc M, Stone WL, Menter DG, Newman RA, Yang P, Aggarwal BB, Krishnan K. γ-Tocotrienol induces growth arrest through a novel pathway with TGFβ2 in prostate cancer. Free Radical Biology & Medicine. 50: 1344-54. PMID 21335085 DOI: 10.1016/J.Freeradbiomed.2011.02.007 |
0.366 |
|
| 2011 |
Li J, Suraokar MB, Tsavachidou D, Menter DG, Kim J. Abstract 4612: Cell-type dependent responses to selenium and knockdown of SBP2 Cancer Research. 71: 4612-4612. DOI: 10.1158/1538-7445.Am2011-4612 |
0.414 |
|
| 2010 |
Kim SH, Xia D, Kim SW, Holla V, Menter DG, Dubois RN. Human enhancer of filamentation 1 Is a mediator of hypoxia-inducible factor-1alpha-mediated migration in colorectal carcinoma cells. Cancer Research. 70: 4054-63. PMID 20442290 DOI: 10.1158/0008-5472.Can-09-2110 |
0.348 |
|
| 2010 |
Menter DG, Schilsky RL, DuBois RN. Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 1384-90. PMID 20179228 DOI: 10.1158/1078-0432.Ccr-09-0788 |
0.341 |
|
| 2010 |
Xia D, Holla VR, Wang D, Menter DG, DuBois RN. HEF1 is a crucial mediator of the proliferative effects of prostaglandin E(2) on colon cancer cells. Cancer Research. 70: 824-31. PMID 20068165 DOI: 10.1158/0008-5472.Can-09-2105 |
0.434 |
|
| 2010 |
Xia D, Wang D, Menter DG, DuBois RN. Abstract B39: Prostaglandin E2 induces human enhancer of filamentation 1 to promote the cell motility of colorectal carcinoma cells Cancer Prevention Research. 3. DOI: 10.1158/1940-6207.Prev-09-B39 |
0.402 |
|
| 2010 |
Xia D, Menter DG, DuBois RN. Abstract 5298: Human enhancer of filamentation 1 induction by Prostaglandin E2 enhances the cell motility of colorectal cancer cells Cancer Research. 70: 5298-5298. DOI: 10.1158/1538-7445.Am10-5298 |
0.414 |
|
| 2009 |
Yang P, Menter DG, Cartwright C, Chan D, Dixon S, Suraokar M, Mendoza G, Llansa N, Newman RA. Oleandrin-mediated inhibition of human tumor cell proliferation: importance of Na,K-ATPase alpha subunits as drug targets. Molecular Cancer Therapeutics. 8: 2319-28. PMID 19671733 DOI: 10.1158/1535-7163.Mct-08-1085 |
0.328 |
|
| 2009 |
Tsavachidou D, McDonnell TJ, Wen S, Wang X, Vakar-Lopez F, Pisters LL, Pettaway CA, Wood CG, Do KA, Thall PF, Stephens C, Efstathiou E, Taylor R, Menter DG, Troncoso P, et al. Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. Journal of the National Cancer Institute. 101: 306-20. PMID 19244175 DOI: 10.1093/Jnci/Djn512 |
0.31 |
|
| 2008 |
Jin Q, Menter DG, Mao L, Hong WK, Lee HY. Survivin expression in normal human bronchial epithelial cells: an early and critical step in tumorigenesis induced by tobacco exposure. Carcinogenesis. 29: 1614-22. PMID 18635526 DOI: 10.1093/Carcin/Bgm234 |
0.344 |
|
| 2005 |
Kim J, Yang P, Suraokar M, Sabichi AL, Llansa ND, Mendoza G, Subbarayan V, Logothetis CJ, Newman RA, Lippman SM, Menter DG. Suppression of prostate tumor cell growth by stromal cell prostaglandin D synthase-derived products. Cancer Research. 65: 6189-98. PMID 16024620 DOI: 10.1158/0008-5472.Can-04-4439 |
0.357 |
|
| 2005 |
Subbarayan V, Xu XC, Kim J, Yang P, Hoque A, Sabichi AL, Llansa N, Mendoza G, Logothetis CJ, Newman RA, Lippman SM, Menter DG. Inverse relationship between 15-lipoxygenase-2 and PPAR-gamma gene expression in normal epithelia compared with tumor epithelia. Neoplasia (New York, N.Y.). 7: 280-93. PMID 15799828 DOI: 10.1593/Neo.04457 |
0.369 |
|
| 2004 |
Yang P, Chan D, Felix E, Cartwright C, Menter DG, Madden T, Klein RD, Fischer SM, Newman RA. Formation and antiproliferative effect of prostaglandin E(3) from eicosapentaenoic acid in human lung cancer cells. Journal of Lipid Research. 45: 1030-9. PMID 14993240 DOI: 10.1194/Jlr.M300455-Jlr200 |
0.328 |
|
| 2004 |
Salas TR, Kim J, Vakar-Lopez F, Sabichi AL, Troncoso P, Jenster G, Kikuchi A, Chen SY, Shemshedini L, Suraokar M, Logothetis CJ, DiGiovanni J, Lippman SM, Menter DG. Glycogen synthase kinase-3 beta is involved in the phosphorylation and suppression of androgen receptor activity. The Journal of Biological Chemistry. 279: 19191-200. PMID 14985354 DOI: 10.1074/Jbc.M309560200 |
0.703 |
|
| 2003 |
Salas TR, Reddy SA, Clifford JL, Davis RJ, Kikuchi A, Lippman SM, Menter DG. Alleviating the suppression of glycogen synthase kinase-3beta by Akt leads to the phosphorylation of cAMP-response element-binding protein and its transactivation in intact cell nuclei. The Journal of Biological Chemistry. 278: 41338-46. PMID 12900420 DOI: 10.1074/Jbc.M302972200 |
0.697 |
|
| 2003 |
Xu XC, Shappell SB, Liang Z, Song S, Menter D, Subbarayan V, Iyengar S, Tang DG, Lippman SM. Reduced 15S-lipoxygenase-2 expression in esophageal cancer specimens and cells and upregulation in vitro by the cyclooxygenase-2 inhibitor, NS398. Neoplasia (New York, N.Y.). 5: 121-7. PMID 12659684 DOI: 10.1016/S1476-5586(03)80003-9 |
0.403 |
|
| 2000 |
Papadimitriou MNB, McIntire LV, Menter DG. Effect of cyclooxygenase inhibitors in the adhesion of tumor cells to endothelial cells Critical Reviews in Biomedical Engineering. 28: 193-194. PMID 10999385 DOI: 10.1615/Critrevbiomedeng.V28.I12.320 |
0.328 |
|
| 1999 |
Papadimitriou MNB, Menter DG, Konstantopoulos K, Nicolson GL, McIntire LV. Integrin α4β1/VCAM-1 pathway mediates primary adhesion of RAW117 lymphoma cells to hepatic sinusoidal endothelial cells under flow Clinical and Experimental Metastasis. 17: 669-676. PMID 10919712 DOI: 10.1023/A:1006747106885 |
0.349 |
|
| 1997 |
Herrmann JL, Menter DG, Beham A, Eschenbach Av, McDonnell TJ. Regulation of lipid signaling pathways for cell survival and apoptosis by bcl-2 in prostate carcinoma cells. Experimental Cell Research. 234: 442-451. PMID 9260915 DOI: 10.1006/Excr.1997.3653 |
0.319 |
|
| 1997 |
Yun Z, Smith TW, Menter DG, McIntire LV, Nicolson GL. Differential adhesion of metastatic RAW117 large-cell lymphoma cells under static or hydrodynamic conditions: role of integrin alpha(v) beta3. Clinical & Experimental Metastasis. 15: 3-11. PMID 9009100 DOI: 10.1023/A:1018451616309 |
0.304 |
|
| 1996 |
Smith TW, Yun Z, Menter DG, McIntire LV, Nicolson GL. Computerized analysis of tumor cell interactions with extracellular matrix proteins, peptides, and endothelial cells under laminar flow. Biotechnology and Bioengineering. 50: 598-607. PMID 18627023 DOI: 10.1002/(Sici)1097-0290(19960605)50:5<598::Aid-Bit15>3.0.Co;2-F |
0.322 |
|
| 1995 |
Nicolson GL, Menter DG. Trophic factors and central nervous system metastasis Cancer and Metastasis Reviews. 14: 303-321. PMID 8821092 DOI: 10.1007/Bf00690600 |
0.326 |
|
| 1995 |
Menter DG, Fitzgerald L, Patton JT, McIntire LV, Nicolson GL. Human melanoma integrins contribute to arrest and stabilization potential while flowing over extracellular matrix. Immunology and Cell Biology. 73: 575-83. PMID 8713481 DOI: 10.1038/Icb.1995.91 |
0.322 |
|
| 1995 |
Menter DG, Herrmann JL, Nicolson GL. The role of trophic factors and autocrine/paracrine growth factors in brain metastasis Clinical & Experimental Metastasis. 13: 67-88. PMID 7882617 DOI: 10.1007/Bf00133612 |
0.304 |
|
| 1994 |
Nicolson GL, Menter DG, Herrmann J, Cavanaugh P, Jia L, Hamada J, Yun Z, Nakajima M, Marchetti D. Tumor Metastasis to Brain: Role of Endothelial Cells, Neurotrophins, and Paracrine Growth Factors Critical Reviews in Oncogenesis. 5: 451-471. PMID 8519808 DOI: 10.1615/Critrevoncog.V5.I5.20 |
0.337 |
|
| 1994 |
Nicolson GL, Nakajima M, Herrmann JL, Menter DG, Cavanaugh PG, Park JS, Marchetti D. Malignant melanoma metastasis to brain: role of degradative enzymes and responses to paracrine growth factors Journal of Neuro-Oncology. 18: 139-149. PMID 7964976 DOI: 10.1007/Bf01050420 |
0.303 |
|
| 1993 |
Marchetti D, Menter DG, Jin L, Nicolson GL, Nakajima M. Nerve growth factor effects on human and mouse melanoma cell invasion and heparanase production International Journal of Cancer. 55: 692-699. PMID 8407001 DOI: 10.1002/Ijc.2910550430 |
0.306 |
|
| 1993 |
Herrmann JL, Menter DG, Hamada JI, Marchetti D, Nakajima M, Nicolson GL. Mediation of NGF-stimulated extracellular matrix invasion by the human melanoma low-affinity p75 neurotrophin receptor: melanoma p75 functions independently of trkA. Molecular Biology of the Cell. 4: 1205-1216. PMID 8305739 DOI: 10.1091/Mbc.4.11.1205 |
0.356 |
|
| 1993 |
Patton JT, McIntire LV, Menter DG, Nicolson GL. Tumor Cell - Substrate Stabilization Mediated by Integrins Mrs Proceedings. 331: 147. DOI: 10.1557/Proc-331-147 |
0.305 |
|
| Show low-probability matches. |